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Available online 28 January 2016Background: Carcinoma of unknownprimary (CUP) of thepelvis is a challenging entity for the oncologist. The role
of human papilloma virus (HPV)/p16 in carcinogenesis and prognosis is more established in the head and neck
than in the pelvis. In the case of anHPVpositive occult primary of the pelvis the radiation therapy target coverage
is not well established.
Case reports: Case#1: A 69-year-old female with a left retroperitoneal and pelvic mass was treated with chemo-
radiation to a dose of 45 Gy in 25 fractions to elective lymph node regions and simultaneous boost to FDG-avid
lymph nodes to 55 Gy in 25 fractions. A post-treatment PET-CT showed complete response of disease now
7months post treatment. Case#2: A 58-year-old female with a large left retroperitoneal pelvic mass was treated
post-operatively with chemoradiation to 45 Gy in 25 fractions with a pelvic boost to 54 Gy. She is clinically and
radiographically with no evidence of disease at 4 years. Case#3: A 47-year-old female with left sided retroperi-
toneal pelvic mass that declined therapy. She ultimately died of progressive disease at 1 year after diagnosis.
Conclusion: Cisplatin based chemoradiation is effective for treating HPV/p16+ pelvic squamous cell cancers of
unknown primary as long as the mass, regional lymph nodes and high risk pelvic primary sites are adequately
covered.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Only 3–5% of all invasive cancers are classiﬁed as cancer of an un-
known primary (CUP) (Fizazi et al., 2015; Greco and Hainsworth, 2009).
Of these, approximately 5%–10% are squamous cell carcinomas (SCCs),
many of which are human papillomavirus (HPV) positive and are most
commonly located in the head and neck. HPV positive CUP SCCs in the
retroperitoneum are exceedingly rare and as such there is not much is
known about the etiology, pathogenesis, or ideal therapy (Clements
et al., 2010; Oh et al., 2015; Chiec et al., 2014). These lesions likely rep-
resent lymphatic metastases from an occult primary and either surgical
resection or deﬁnitive chemoradiation have been suggested to provide
reasonable outcomes (Clements et al., 2010; Boneschi et al., 1999).
In the more common situation of SCC of unknown primary of the
head and neck, HPV is a useful tool as it helps identify the mucosal at-
risk primary site. Typically the deﬁnitive management for these cancers
is with chemoradiation, as there is a strong link between HPV positivity
and p16 overexpression with tumors that originate in the oropharynx
(Fotopoulos and Pavlidis, 2015). In pelvic or retroperitoneal SCC of un-
known primary HPV status may also be used as a guide to determinecology, Virginia Commonwealth
s).
. This is an open access article underthe at-riskmucosal sites. HPV is a common cause of genital, gynecologic
and anal cancerswith rates of 50% for vulvar cancers, 64–91% for vaginal
cancers, 95% for cervical cancers and 90% for anal cancers (Parkin and
Bray, 2006). However, HPV is rarely positive in endometrial or ovarian
cancers (Ansari-Lari et al., 2004; Staebler et al., 2002; Lee et al., 2009;
Idahl et al., 2010). These statistics in addition to patient risk factors, clin-
ical presentation, and imaging ﬁndingsmay be used to guide treatment.
In this manuscript, we report on three cases of HPV positive pelvic
and retroperitoneal SCC of unknown primary to build on the literature
and to relate the approach to treatment to the more common situation
found in CUP in the head and neck region.
2. Case reports
2.1. Case#1
69 year old female who presented with a right inguinal mass, left
upper thigh numbness and pain for 3months. She underwent excisional
biopsy of the right inguinal mass, which was consistent with grade 3 A
follicular lymphoma (CD 10, 20 and BCL 6 positive) and bone marrow
biopsy was negative. This led to CT abdomen, which identiﬁed a left-
sided retroperitoneal mass. CT-guided biopsy showed metastatic carci-
nomawith squamous cell differentiation. The lymphoma and squamous
malignancy were not felt to be related and as the lymphoma was stagethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. FDG PET/CT fused axial images showing (A) the left pelvic mass pre-treatment and (B) complete response to treatment with chemoradiation.
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medical history was signiﬁcant only for a total abdominal hysterectomy
and bilateral salpingo-oophorectomy performed for benign reasons
approximately 20 years ago.
PET/CT was done and showed the left retroperitoneal mass
(2.7 × 1.8 cm) as well as a left-sided pelvic mass (3.6 × 2.6 cm)
with ureteral obstruction (Fig. 1a). Exam under anesthesia (EUA) with
cystoscopy, anal colposcopy and directed biopsies of the anogenital re-
gion revealed no evidence of a primary. Otolaryngology work up was
normal. Urology subsequently performed excisional biopsy of pelvic
lymph nodes with ureterolysis to try to obtain more tissue and relieve
pressure from the collecting system. The left pelvic mass showedmeta-
static squamous cell carcinoma strongly p16 positive consistent with
high risk HPV involvement.
Recommendation was for chemoradiation and patient was treated
with volumetric modulated arc therapy (VMAT) in order to encompass
such a large volume of disease and the bilateral inguinal regions. She
received 45 Gy in 25 fractions of 1.8 Gy to elective lymph node regions
with a simultaneous integrated boost to FDG-avid lymph nodes to 55Gy
in 25 fractions (Fig. 2 a–c). The superior ﬁeld borderwas extended to L2/
3 to cover a full vertebral body above the grossly involved nodes. Inferi-
orly, although the punitive mucosal site was not identiﬁed, the vaginal
cuff and upper 1/3 of the vaginal canal were included. She received
weekly cisplatin at 40 mg/m2 concurrently.
Three months post-treatment a PET/CT scan showed a complete re-
sponse in the pelvic and retroperitoneal lymph nodes (Fig. 1b), but with
interval development of a right middle lobe nodule with an SUV of 5.
Patient underwent a right middle lobectomy and pathology showed
necrotizing granulomas. She is alive and well with no evidence of dis-
ease 7 months post treatment.2.2. Case#2
58 year old female who presented with left hip pain. A CT of the ab-
domen and pelvis showed a 6.7 × 7 cm retroperitoneal mass extending
to the left pelvic side wall.Fig. 2. VMAT treatment plan to 45Gy (red color wash) with an integrated boost to 55Gy (Her gynecologic history is signiﬁcant for a total abdominal hysterecto-
my and bilateral salpingo-oopherectomy 15 years ago for endometriosis,
however, she reports multiple colposcopies for cervical intraepithelial
neoplasia III.
Shehad a PET/CT aswell as EUAwith directed biopsieswithout iden-
tiﬁcation of a primary site of disease. At an outside hospital, she
underwent an exploratory laparotomy for pelvic mass resection and
was found to have disease adherent to the bladder, vaginal and left pel-
vic side wall. Pathology showed p16 positive poorly differentiated SCC.
She received post-operative cisplatin-based chemoradiation to
45 Gy in 25 fractions to the whole pelvis using a 3D four ﬁeld technique
which covered the vaginal cuff and upper 1/3 of the vagina. This was
followed by a boost of 9Gy using a 3D three ﬁeld oblique technique
for a total dose of 54 Gy. The pelvic ﬁeld borders extended from L4/5
down to the obturator foramen and posteriorly included the sacrum.
The reason for using 3D conformal with a sequential boost vs. IMRT is
unknown as she received treatment at an outside hospital. Unfortunate-
ly, during this process she was hospitalized repeatedly for small bowel
obstructions.
Now, 4 years later, Patient 2 began to develop severe abdominal
pain. She was noted to have hematuria and was treated for multiple
UTIs. She underwent cystoscopy with biopsy and was found to have
stromal ﬁbrosis consistent with late radiation changes. She is currently
clinically and radiographically with no evidence of disease.2.3. Case#3
47 year old G11P9 female who initially presented with several
weeks of left leg pain. She had a CT scan of the chest, abdomen and pel-
vis which showed a left pelvic side wall mass in the location of an ex-
pected left ovary causing compression of the left common iliac vein
with thrombosis in the left external iliac and femoral veins. She was
taken to the OR at the outside facility where a biopsy was obtained of
the pelvic sidewall mass. Pathology from the small specimen that was
obtained was reviewed here and showed a high grade malignant neo-
plasm with extensive necrosis.purple color wash) with (A) axial, (B) sagittal and (C) coronal representative images.
Fig. 3. Maximal intensity projection image at presentation showing the large FDG avid
mass in the left pelvis.
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mass measuring 7.4 × 6.5 × 6.9 cmwith central necrosis with an SUV of
15.1, a more superior lesion resembling a periaortic lymph node mea-
suring 2.5 × 3.6 × 1.7 cmwith an SUV of 12.1 (Fig. 3). EUAwith cervical
pap test, high resolution anoscopy and directed biopsies revealed no
primary lesion.
To obtain more tissue, ultrasound guided biopsy of the left pelvic
mass with FNA showed p16 positive moderately differentiated squa-
mous cell carcinoma.
She was recommended chemoradiation upfront vs. induction che-
motherapy followed by chemoradiation vs. palliative radiotherapy for
pain control, but ultimately opted not to receive any treatment. She
passed away of progressive disease 1 year after her diagnosis.Table 1
Presentation and histology of the 10 cases of pelvic HPV/p16+ SCC of unknown primary.
Pt Presentation Locati
1 56 year old female with left pelvic mass found incidentally
on ultrasound for routine health evaluation
Left re
2 34 year old female with right sided DVT Right
3 27 year old female with left sided DVT Left p
4 43 year old female unknown presentation Left p
5 44 year old female with left sided DVT Left p
6 52 year old female with right sided DVT Right
7 54 year old female unknown presentation Right
8 69 year old female with a right inguinal mass,
left upper thigh numbness and pain for 3 months
Left re
9 58 year old female with left hip pain Left re
10 47 year old female with several weeks of left leg pain Left re
Pt 1: Ref. Oh et al., 2015.
Pts 2–7: Ref. Clements et al., 2010.
Pts 8–10: current series.
IHC: Immunohistochemistry.3. Discussion
Presentation with pelvic or retroperitoneal HPV/p16 positive squa-
mous cell carcinoma of unknown primary is rare. These 3 cases add to
the 7 previously reported cases in the literature to date (Table 1)
(Clements et al., 2010; Oh et al., 2015; Chiec et al., 2014). In each case,
the women were worked up in a manner analogous to that of patients
presenting with neck nodes with an unknown primary of the head
and neck. Each patient had a thorough evaluation to determine the pri-
mary site of disease including EUAwith biopsies and PET/CT, but no pri-
marywas identiﬁed. In head and neck cancer presentingwith unknown
primary, the primary is felt to be a small/submucosal tumor, to have had
spontaneous regression or yet tomanifest. HPV or p16 status is relied on
as a tool to identify potential mucosal at-risk sites and to improve
targeting of the chemoradiation. With pelvic or retroperitoneal SCC of
unknown primary, HPV/p16 status can be similarly useful. In the cases
presented, the anal mucosa was not covered as a high risk mucosal
site, as it was considered lower risk in these cases based on history. In
a patient with risk factors for anal cancer, however, this may need to
be included as a target.
Retroperitoneal adenopathy at diagnosis is inherently considered
metastatic disease, however, from these series, there is growing evidence
to suggest that with aggressive management with cisplatin-based
chemoradiation the outcomes may be comparable to locally advanced
cervical or anal cancers. In our series, the 2womenwho received chemo-
radiation therapy are alive and without evidence of disease (one at
7 months and the other at 4 years). Similarly, in the series from
MDACC,women treatedwith chemoradiationwere alivewith orwithout
disease for an average of 22 months (range 6–48 months) (Table 2)
(Clements et al., 2010). Larger series of a more diverse group of patients
with unknown primaries of the abdomen and pelvis have also shown
survival beneﬁts using deﬁnitive radiotherapy (Kelly et al., 2012).
In this series, eachwomanpresentedwith hip pain andwas found to
have large volume disease in the pelvis and retroperitoneum. Interest-
ing, there is variation in the literature of presentation, including more
occult presentations such as incidental ﬁnding on transvaginal ultra-
sound and DVT (Table 1) (Clements et al., 2010; Oh et al., 2015).
Although CUP in the head and neck is uncommon, it can be diagnosed
at an earlier stage as the cervical neck nodes are visible and noticeable
to a patient prior to causing other symptoms. It is a possibility that
CUP in the pelvis and retroperitoneum is actually more common than
is reported, but is not found until disease becomes symptomatic.
This series is inherently limited by a small number of cases and
retrospective nature. Although we are not able to determine whether
HPV/p16 caused these squamous cell cancers, it is a helpful tool to devel-
op a treatment paradigm with reasonable outcomes in these patients.
The authors have no ﬁnancial or other conﬂict of interests to report.on of mass Histology IHC
troperitoneal parametrium Squamous HPV 18+
psoas Squamous HPV−/p16+
soas Squamous P16+
soas Poorly differentiated HPV+/p16+
soas Poorly differentiated HPV+/p16+
psoas, liver and lung mets Poorly differentiated HPV+/p16+
pelvic lymph node Squamous HPV+/p16+
troperitoneum Squamous HPV+/p16+
troperitoneum Poorly differentiated P16+
troperitoneum Squamous P16+
Table 2
Treatment and outcomes of the 10 cases of pelvic HPV/p16+ SCC of unknown primary.
Pt Treatment Radiation details Clinical outcomes
1 Complete resection and left pelvic lymph node dissection followed
by chemotherapy with cisplatin/5-FU and planned RT
Not described Not reported
2 Chemoradiation with cisplatin 40 Gy/10 fx to the pelvis followed by 10 Gy/4 fx
for persistent pain
Stable disease for 1 year with progression in
cervix, alive with disease at 23 months
3 Taxol or carboplatin with progression followed by deﬁnitive
chemoradiation
45 Gy to the pelvis followed by IMRT boost to
63 Gy to gross disease
Died of disease at 1 year
4 Palliative radiation with multiple chemotherapy regimens at relapse 45 Gy/25 fx to the pelvis Progression in primary tumor and regional nodes
at 1 year
5 Taxol or carboplatin followed by deﬁnitive chemoradiation 45 Gy to the pelvis followed by IMRT boost to
63 Gy to gross disease
NED at 6 months
6 Palliative radiation with multiple chemotherapy regimens at relapse 10 Gy × 1 to the pelvis repeated at 6 weeks Died of disease at 8 months
7 Resection followed by chemoradiation with carboplatin Initial RT not none, but received 66 Gy at the
time of recurrence
NED at 48 months
8 Resection with residual gross disease followed by chemoradiation
with weekly cisplatin
IMRT to 55 Gy/25 fx to gross disease and
45 Gy/25 fx to at-risk nodal regions
NED at 7 months
9 Resection with residual gross disease followed by chemoradiation
with weekly cisplatin
45 Gy/25 fx to the pelvis with conformal RT
followed a boost to 54 Gy to gross disease
NED at 4 years
10 Refused therapy None Died of disease at 1 year
Pt 1: Ref. Oh et al., 2015.
Pts 2–7: Ref. Clements et al., 2010.
Pts 8–10: current series.
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